Filing Flows › IGC Pharma (IGC) › Q4 2024
IGC Pharma (IGC) Q4 2024 earnings results (fourth quarter 2024)
10-Q filed Feb 14, 2025
IGC Pharma (IGC) reported revenue of $257K for the fourth quarter 2024 (Q4 2024), +26% from a year earlier and -38% from the quarter before. Operating margin was -730.7%, net loss $1.8M (711.7% of revenue).
IGC Pharma, Q4 2024: revenue $257K (+26% year over year), operating margin -730.7%, net loss $1.8M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $257K | -38% | +26% |
| Operating profit | −$1.9M | — | — |
| Net earnings | −$1.8M | — | — |
| Operating cash flow | −$1.3M | — | — |
What changed
Revenue was $257K in Q4 2024, up 26% year over year and down 38% from the previous quarter. White Labeling Services was the largest line at 87% of revenue. White Labeling Services added $66K year over year (up 42%), 125% of the total change. Wellness and Lifestyle declined 28%.
Gross margin was 40.5%, down 24.7 points from a year earlier. Operating costs exceeded revenue by $1.9M, an operating margin of -730.7%. Operating expenses fell 37% while revenue rose 26%. The quarter ended with a net loss of $1.8M, wider than the previous quarter's $1.7M loss.
Operating cash flow was −$1.3M. Non-cash charges added back $157K of depreciation and amortization. Working capital and other items added $355K. Capital expenditures of $27K exceeded it, leaving free cash flow of −$1.3M.
Questions
What was IGC Pharma's revenue in the fourth quarter 2024?
IGC Pharma (IGC) reported revenue of $257K for the fourth quarter 2024 (Q4 2024), +26% from a year earlier and -38% from the quarter before.
Was IGC Pharma profitable in the fourth quarter 2024?
Operating loss was $1.9M (-730.7% of revenue) and net loss $1.8M.
Source: IGC Pharma 10-Q on SEC EDGAR.